摘要
背景:日常生活工具活动(IADL)是一种复杂的活动,涉及多种认知过程,容易受到认知的早期影响。损伤。以线人为基础的问卷是评估痴呆患者IADL表现的最常用工具,但在早期损伤阶段必须加以调整。 目的:探讨认知功能减退(无认知下降-主观认知功能减退-轻度认知功能损害-轻度痴呆-中度认知功能衰退)在认知功能障碍(IADL)上的差异。痴呆症)使用西班牙版的阿姆斯特丹IADL问卷(A-IADL-Q)。 方法:包括500名志愿者:88名无认知减退症状的参与者,109名主观认知投诉的参与者,114名轻度认知功能减退的参与者。轻度痴呆81例,中度痴呆108例。评估IADL的方法是A-IADL-Q,这是一份计算机化的自适应问卷,计算的是核心根据每个参与者的具体反应模式。资料采用ANOVAS和回归分析。用多项Logistic回归分析评价ca。A-IADL-Q的频域区分诊断组. 结果:无认知下降和主观认知功能下降的受试者A-IADL-Q得分高于MCI组,MCI组高于MCI组。痴呆症患者。A-IADL-Q对非认知障碍和痴呆有很好的鉴别能力,对非认知功能障碍和MCI的区分程度显著但低。 结论:α-IADL-Q能在不同痴呆谱组间鉴别IADL的功能.
关键词: 日常生活工具活动、阿姆斯特丹IADL问卷、日常活动、主观认知能力下降、轻度认知障碍、痴呆、多项Logistic回归分析。
Current Alzheimer Research
Title:Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire
Volume: 15 Issue: 13
关键词: 日常生活工具活动、阿姆斯特丹IADL问卷、日常活动、主观认知能力下降、轻度认知障碍、痴呆、多项Logistic回归分析。
摘要: Background: Instrumental activities of daily living (IADL) are complex activities which involve multiple cognitive processes, and which are expected to be susceptible to the early effects of cognitive impairment. Informant-based questionnaires are the most common tools used to assess IADL performance in dementia, but must be adjusted for use in early stages of impairment.
Objective: To investigate the differences in IADL on the continuum of cognitive decline (i.e. no cognitive decline - subjective cognitive decline - mild cognitive impairment- mild dementia - moderate dementia) using the Spanish version of the Amsterdam IADL Questionnaire (A-IADL-Q).
Methods: A total of 500 volunteer participants were included: 88 participants with no signs of cognitive decline, 109 participants with subjective cognitive complaints, 114 participants with mild cognitive impairment (MCI), 81 participants with mild dementia and 108 participants with moderate dementia. IADL was assessed with the A-IADL-Q, a computerized and adaptive questionnaire that calculates scores according to the specific pattern of responses of each participant. The data were examined by ANOVAs and regression analysis. Multinomial logistic regression analysis was used to evaluate the capacity of the A-IADL-Q to distinguish between diagnostic groups.
Results: Participants with no cognitive decline and those with subjective cognitive decline obtained higher A-IADL-Q scores than MCI participants, and participants with MCI obtained higher scores than patients with dementia. The A-IADL-Q showed excellent discrimination between non-cognitive impairment and dementia, and significant but low discrimination between non-cognitive impairment and MCI.
Conclusion: A-IADL-Q can discriminate IADL functioning between groups across the dementia spectrum.
Export Options
About this article
Cite this article as:
Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire, Current Alzheimer Research 2018; 15 (13) . https://dx.doi.org/10.2174/1567205015666180925113411
DOI https://dx.doi.org/10.2174/1567205015666180925113411 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Microwave Assisted One-pot Three Component Synthesis of Novel 2-(5- Aryloxymethyl-1,3,4-thiadiazolo)-3-aryl-4-thiazolidinones
Letters in Organic Chemistry n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Citalopram-Associated Alopecia: A Case Report and Brief Literature Review
Current Drug Safety Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
Current Neuropharmacology Review of Bioinformatics and Theoretical Studies of Acetylcholinesterase Inhibitors
Current Bioinformatics L1CAM Beneficially Inhibits Histone Deacetylase 2 Expression under Conditions of Alzheimer’s Disease
Current Alzheimer Research Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture A Review on the Effects of Testosterone Supplementation in Hypogonadal Men with Cognitive Impairment
Current Drug Targets Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Defining Dystonic Tremor
Current Neuropharmacology PP2A and Alzheimer Disease
Current Alzheimer Research Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology